During the past decade, NYU Hepatology Associates conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "NYU Hepatology Associates" are "Hepatitis B" (1 trials), "Hepatitis B, Chronic" (1 trials), "Hepatitis C, Chronic" (1 trials) and "Primary Biliary Cirrhosis" (1 trials). Many other conditions were trialed in "NYU Hepatology Associates" in a lesser frequency.

Most popular intervention types in "NYU Hepatology Associates" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "JNJ-56136379" (2 trials), "Copegus®" (1 trials), "GKT137831" (1 trials), "GS-9451" (1 trials) and "GS-9451 placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "NYU Hepatology Associates" are 4 trials for "All" genders.

Currently, there are NaN active trials in "NYU Hepatology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in NYU Hepatology Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in NYU Hepatology Associates, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".